Dermata Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.79 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.11Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $5.5M Enterprise Value −$1.4M Shares Outstanding 5M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Dermata Therapeutics is undergoing a high-stakes strategic pivot from a traditional clinical-stage prescription drug developer to a direct-to-consumer (DTC) and B2B cosmetic skincare brand under the newly unveiled 'Tome' brand. Despite achieving statistically significant Phase 3 STAR-1 clinical trial results for its lead acne candidate XYNGARI (DMT310) in early 2025, management chose to withdraw its IND and exit the costly, lengthy FDA prescription approval pathway. Instead, the company is leveraging its proprietary Spongilla lacustris-derived Bioneedle technology to launch faster-to-market consumer products, starting with the Tome Foundational Treatment mask in mid-2026. While this pivot dramatically reduces regulatory burdens and clinical R&D expenses, it introduces intense commercial execution risks, brand-building costs, and a complete shift in the company's core competencies. With cash of $6.9 million as of March 31, 2026, providing a runway into Q1 2027, and a newly filed $100 million shelf registration creating dilution overhang, a 'Hold' rating is recommended until early commercial traction and revenue generation of the Tome brand can be validated. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$4.00 Mean target$4.00 High · most bullish analyst$4.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Dermata struggles to establish brand equity for Tome in an extremely crowded and competitive DTC skincare market. High customer acquisition costs (CAC) drain the company's remaining cash reserves faster than expected, while initial sales fail to gain traction. The company is forced to execute highly dilutive equity raises under its $100 million shelf registration at depressed share prices to sustain operations, severely eroding shareholder value. Regulatory scrutiny under MoCRA or manufacturing issues with Spongilla lacustris further delay product rollouts. Base CaseCentral scenario The company successfully launches the Tome Foundational Treatment in mid-2026, followed by the Tome Clearing Treatment acne system. Marketing expenses rise, but are offset by the elimination of expensive Phase 3 clinical trials. Initial DTC e-commerce sales and professional B2B aesthetician partnerships begin generating modest revenues in late 2026, validating the commercial viability of the Spongilla technology in the consumer space. The cash runway is extended into 2027 through disciplined spending and minor, non-disruptive capital raises under the shelf registration. Bull CaseUpside scenario Dermata's lead product candidate, Xyngari (formerly DMT310), is a novel, once-weekly topical treatment derived from a naturally sourced freshwater sponge (Spongilla technology platform). In March 2025, Xyngari successfully met all primary endpoints in its pivotal Phase 3 STAR-1 clinical trial for moderate-to-severe acne, demonstrating highly statistically significant and clinically meaningful improvements in inflammatory and non-inflammatory lesions with a favorable safety profile. The company plans to initiate its second Phase 3 trial (STAR-2) in the second half of 2025, which, if positive, will support a New Drug Application (NDA) filing with the FDA. If approved, Xyngari could become the first and only once-weekly topical product for acne, addressing a massive market of over 30 million patients seeking treatment in the U.S. annually. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |